These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11948132)

  • 1. Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
    Sun D; Urrabaz R; Kelly S; Nguyen M; Weitman S
    Clin Cancer Res; 2002 Apr; 8(4):1189-95. PubMed ID: 11948132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1.
    Prakasha Gowda AS; Polizzi JM; Eckert KA; Spratt TE
    Biochemistry; 2010 Jun; 49(23):4833-40. PubMed ID: 20459144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells.
    Sun D; Urrabaz R; Buzello C; Nguyen M
    Exp Cell Res; 2002 Oct; 280(1):90-6. PubMed ID: 12372342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of inhibition of DNA ligase in Ara-C treated cells.
    Zittoun J; Marquet J; David JC
    Leuk Res; 1991; 15(2-3):157-64. PubMed ID: 2016906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
    Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
    Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
    Pourquier P; Gioffre C; Kohlhagen G; Urasaki Y; Goldwasser F; Hertel LW; Yu S; Pon RT; Gmeiner WH; Pommier Y
    Clin Cancer Res; 2002 Aug; 8(8):2499-504. PubMed ID: 12171875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cisplatin on expression of DNA ligases in MiaPaCa human pancreatic cancer cells.
    Sun D; Urrabaz R; Buzello C; Nguyen M
    Biochem Biophys Res Commun; 2002 Nov; 298(4):537-44. PubMed ID: 12408985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
    Wong SJ; Myette MS; Wereley JP; Chitambar CR
    Clin Cancer Res; 1999 Feb; 5(2):439-43. PubMed ID: 10037195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
    Shi Z; Azuma A; Sampath D; Li YX; Huang P; Plunkett W
    Cancer Res; 2001 Feb; 61(3):1065-72. PubMed ID: 11221834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle effects of gemcitabine.
    Cappella P; Tomasoni D; Faretta M; Lupi M; Montalenti F; Viale F; Banzato F; D'Incalci M; Ubezio P
    Int J Cancer; 2001 Aug; 93(3):401-8. PubMed ID: 11433406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
    Iwasaki H; Huang P; Keating MJ; Plunkett W
    Blood; 1997 Jul; 90(1):270-8. PubMed ID: 9207462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
    Cory AH; Hertel LW; Kroin JS; Cory JG
    Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.